Avadel Pharmaceuticals Issues Statement On Patent Litigation
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
- DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.
- Avadel is pleased with the jury’s decision ruling in favor of Avadel with respect to one of the contested patents.
- As it relates to the jury’s decision against Avadel regarding the additional contested patent, the company is disappointed in the outcome.
- Avadel does not expect the jury’s decision to impact the ongoing commercial launch or potential for LUMRYZ™ to transform the lives of people living with narcolepsy.